Not Yet Recruiting
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
NCT07343453
- Conditions
- Advanced Stage, Second-line Therapy, Thymic Epithelial Tumors
- Locations
-
Not specified